• Dexcom won Health Canada authorization for its G7 15 Day continuous glucose monitoring system for adults aged 18 and older with diabetes.
• The device extends wear time to 15.5 days, aiming to reduce sensor changes and support continuity of monitoring.
• The product is not yet available for purchase in Canada.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713940133) on July 13, 2026, and is solely responsible for the information contained therein.